Analysts Set Medtronic PLC (NYSE:MDT) Price Target at $109.94

Shares of Medtronic PLC (NYSE:MDT) have earned a consensus rating of “Moderate Buy” from the twenty-six ratings firms that are currently covering the company, MarketBeat reports. Eleven research analysts have rated the stock with a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $110.2778.

A number of equities research analysts have recently issued reports on the stock. Daiwa Capital Markets boosted their price objective on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Barclays lifted their target price on Medtronic from $111.00 to $116.00 and gave the company an “overweight” rating in a research report on Thursday. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. JPMorgan Chase & Co. raised their price objective on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Finally, Citigroup lifted their price objective on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th.

Institutional Trading of Medtronic

Several institutional investors and hedge funds have recently modified their holdings of the company. Brighton Jones LLC raised its holdings in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the period. Ashton Thomas Private Wealth LLC grew its position in shares of Medtronic by 12.8% during the first quarter. Ashton Thomas Private Wealth LLC now owns 25,471 shares of the medical technology company’s stock worth $2,307,000 after purchasing an additional 2,895 shares in the last quarter. Fred Alger Management LLC raised its stake in Medtronic by 33.1% during the 1st quarter. Fred Alger Management LLC now owns 48,994 shares of the medical technology company’s stock valued at $4,437,000 after purchasing an additional 12,193 shares during the period. Signature Estate & Investment Advisors LLC raised its stake in Medtronic by 11.2% during the 1st quarter. Signature Estate & Investment Advisors LLC now owns 4,081 shares of the medical technology company’s stock valued at $367,000 after purchasing an additional 410 shares during the period. Finally, Ascent Group LLC lifted its holdings in Medtronic by 113.6% in the 1st quarter. Ascent Group LLC now owns 17,263 shares of the medical technology company’s stock worth $1,551,000 after purchasing an additional 9,180 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

NYSE MDT opened at $97.54 on Thursday. Medtronic has a 52 week low of $79.55 and a 52 week high of $106.33. The firm has a market capitalization of $125.04 billion, a P/E ratio of 26.29, a PEG ratio of 2.57 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The company has a 50-day moving average price of $98.31 and a 200-day moving average price of $94.51.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter last year, the firm posted $1.26 earnings per share. The firm’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s payout ratio is currently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).